• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biosergen

5.20 SEK

+4.00 %

Less than 1K followers

BIOSGN

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.00 %
-41.57 %
-85.14 %
-87.00 %
-86.84 %
-88.47 %
-91.38 %
-98.68 %
-98.59 %

Biosergen is active in biotechnology. The company specializes in the research and development of antifungal drugs. The product portfolio includes, for example, an antifungal drug for the treatment of invasive fungal infections in immunosuppressed patients. The company collaborates with research institutes and pharmaceutical companies internationally. Biosergen was founded in 2004 and is headquartered in Solna.

Read more
Market cap
12.21M SEK
Turnover
45.13K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
19.8
2026

Interim report Q2'26

18.11
2026

Interim report Q3'26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release30.06.2026, 17.00

Bulletin from the annual general meeting of Biosergen AB

Biosergen
Regulatory press release26.06.2026, 17.45

Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie

Biosergen
Regulatory press release26.06.2026, 17.40

Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie

Biosergen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release26.06.2026, 17.35

Flerie and Biosergen have agreed on a merger plan - Flerie's first new investment since its listing on Nasdaq Stockholm

Biosergen
Regulatory press release26.06.2026, 17.30

Biosergen AB: Biosergen Publishes 2025 Annual Report

Biosergen
Regulatory press release28.05.2026, 08.30

Notice of annual general meeting in Biosergen AB

Biosergen
Press release07.04.2026, 14.24

BioStock: Biosergen halts BSG005 development

Biosergen
Regulatory press release04.04.2026, 21.00

Biosergen AB: Biosergen Pauses Development of BSG005

Biosergen
Regulatory press release10.02.2026, 08.30

Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025

Biosergen
Regulatory press release20.11.2025, 08.30

Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen

Biosergen
Press release19.11.2025, 14.54

BioStock: Biosergen comments on continued progress in the third quarter

Biosergen
Regulatory press release19.11.2025, 08.30

Biosergen AB: Biosergen publishes interim report for the third quarter 2025

Biosergen
Regulatory press release28.10.2025, 08.30

Biosergen AB: Biosergen's Nomination Committee appointed

Biosergen
Press release22.09.2025, 13.43

BioStock: ECDC sounds alarm on C. auris – Biosergen eyes role in containment

Biosergen
Press release17.09.2025, 12.04

Carlsquare: Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe

Biosergen
Press release02.09.2025, 15.40

Carlsquare: Research update Biosergen: Ongoing development going according to plan

Biosergen
Press release21.08.2025, 09.52

BioStock: Biosergen’s CEO on the preparations for the next clinical phase

Biosergen
Regulatory press release20.08.2025, 08.30

Biosergen AB: Biosergen publishes its interim report for the second quarter 2025

Biosergen
Press release25.07.2025, 12.16

BioStock: Biosergen strengthens executive team amid clinical momentum

Biosergen
Regulatory press release24.07.2025, 14.12

Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer

Biosergen